IP Library › Granted Patent US 9,663,543
Granted Patent B2
US 9,663,543 · App. 14/631,785 · Granted May 30, 2017

Phosphonate compounds for treatment of complement mediated disorders

Inventors: Jason Allan Wiles (Madison, CT); Akihiro Hashimoto (Branford, CT); Venkat Rao Gadhachanda (Hamden, CT); Godwin Pais (Hamden, CT); Qiuping Wang (Bethany, CT); Dawei Chen (Guilford, CT); Xiangzhu Wang (Branford, CT); Atul Agarwal (Hamden, CT); Milind Deshpande (Madison, CT); Avinash S. Phadke (Branford, CT)
Assignee: Achillion Pharmaceuticals, Inc.
C07F9/5728A61K31/404A61K31/407A61K31/4162A61K31/4178A61K31/4184A61K31/4188A61K31/4192A61K31/437A61K31/4439A61K31/4709A61K31/496A61K31/506A61K31/549A61K31/55A61K31/675A61K31/683C07B59/002C07D209/14C07D209/40C07D209/42C07D401/14C07D403/06C07D403/08C07D403/12C07D403/14C07D405/12C07D405/14C07D413/06C07D413/14C07D417/06C07D417/12C07D417/14C07D471/04C07D487/04C07D487/14C07D491/113C07D495/04C07D513/04C07F5/025C07F5/027C07F7/0812C07F9/6561C07F9/65583C07F9/65616C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,663,543
App. No.
14/631,785
Granted
May 30, 2017
Kind
B2
Abstract

Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is a phosphonate (R 32 ) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

Claims (113)

1. A compound of Formula I

and the pharmaceutically acceptable salts thereof, wherein:

Q 1 is C(R 1 R 1′ );

Q 2 is C(R 2 R 2′ );

Q 3 is C(R 3 R 3′ );

X 1 is N and X 2 is CH;

R 1 , R 1′ , R 2 , R 2′ , R 3 , and R 3′ are independently chosen from hydrogen, halogen, hydroxyl, nitro, cyano, amino, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 2 -C 6 alkynyl, C 2 -C 6 alkanoyl, C 1 -C 6 thioalkyl, hydroxyC 1 -C 6 alkyl, aminoC 1 -C 6 alkyl, —C 0 -C 4 alkylNR 9 R 10 , —C(O)OR 9 , —OC(O)R 9 , —NR 9 C(O)R 10 , —C(O)NR 9 R 10 , —OC(O)NR 9 R 10 , —NR 9 C(O)OR 10 , C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy, where R 9 and R 10 are independently chosen at each occurrence from hydrogen, C 1 -C 6 alkyl, (C 3 -C 7 cycloalkyl)C 0 -C 4 alkyl, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), and —O—C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl);

or R 1 and R 2 form a 3- to 6-membered carbocyclic or aryl ring;

or R 2 and R 3 form a 3- to 6-membered carbocyclic ring;

or R 1 and R 1′ , or R 2 and R 2′ , or R 3 and R 3′ form a 3- to 6-membered carbocyclic spiro ring;

or R 2 and R 2′ or R 3 and R 3′ form a 3- to 6-membered heterocyclic spiro ring;

each of which ring is unsubstituted or substituted with 1 or more substituents independently chosen from halogen, hydroxyl, cyano, —COOH, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, C 2 -C 4 alkanoyl, hydroxyC 1 -C 4 alkyl, (mono- and di-C 1 -C 4 alkylamino)C 0 -C 4 alkyl, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), —O—C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy;

or R 1 and R 1′ or R 2 and R 2′ form a carbonyl group;

A is a group selected from:

R 5 and R 6 are independently selected from —CHO, —C(O)NH 2 , —C(O)NH(CH 3 ), C 2 -C 6 alkanoyl, hydrogen, hydroxyl, halogen, cyano, nitro, —COOH, —SO 2 NH 2 , vinyl, C 1 -C 6 alkyl (including methyl), C 2 -C 6 alkenyl, C 1 -C 6 alkoxy, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), —C(O)C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), —P(O)(OR 9 ) 2 , —OC(O)R 9 , —C(O)OR 9 , —C(O)N(CH 2 CH 2 R 9 )(R 10 ), —NR 9 C(O)R 10 , phenyl, or 5- to 6-membered heteroaryl; and wherein each R 5 and R 6 other than hydrogen, hydroxyl, cyano, and —COOH is unsubstituted or optionally substituted;

R 8 and R 8′ are independently chosen from hydrogen, halogen, hydroxyl, C 1 -C 6 alkyl, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), C 1 -C 6 alkoxy, and (C 1 -C 4 alkylamino)C 0 -C 2 alkyl; or R 8 and R 8′ form an oxo group; or R 8 and R 8′ taken together with the carbon that they are bonded to form a 3-membered carbocyclic ring;

X 11 is N or CR 11 ;

X 12 is CR 12 ;

X 13 is CR 13 ;

X 14 is N or CR 14;

one of R 12 and R 13 is chosen from R 31 and the other of R 12 and R 13 is chosen from R 32 :

R 31 is chosen from hydrogen, halogen, hydroxyl, nitro, cyano, amino, —COOH, C 1 -C 2 haloalkyl, C 1 -C 2 haloalkoxy, C 1 -C 6 alkyl, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), C 2 -C 6 alkenyl, C 2 -C 0 alkanoyl, C 1 -C 6 alkoxy, C 2 -C 6 alkenyloxy, —C(O)OR 9 , C 1 -C 6 thioalkyl, —C 0 -C 4 alkylNR 9 R 10 , —C(O)NR 9 R 10 , —SO 2 R 9 , —SO 2 NR 9 R 10 , —OC(O)R 9 , and —C(NR 9 )NR 9 R 10 , each of which R 31 other than hydrogen, halogen, hydroxyl, nitro, cyano, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy is unsubstituted or substituted with one or more substituents independently selected from halogen, hydroxyl, nitro, cyano, amino, —COOH, —CONH 2 C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy, and each of which R 31 is also optionally substituted with one substituent chosen from phenyl and 4- to 7-membered heterocycle containing 1, 2, or 3 heteroatoms independently chosen from N, O, and S; which phenyl or 4- to 7-membered heterocycle is unsubstituted or substituted with one or more substituents independently chosen from halogen, hydroxyl, nitro, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkanoyl, C 1 -C 6 alkoxy, (mono- and di-C 1 -C 6 alkylamino)C 0 -C 4 alkyl, C 1 -C 6 alkylester, —C 0 -C 4 alkyl)(C 3 -C 7 cycloalkyl), C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy;

R 32 is —P(O)R 20 R 20 ;

R 20 is independently chosen at each occurrence from hydroxyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkyl, (C 3 -C 7 cycloalkyl)C 0 -C 4 alkyl-, (aryl)C 0 -C 4 alkyl-, —O—C 0 -C 4 alkyl(aryl), —O—C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), (4- to 7-membered heterocycloalkyl)C 0 -C 4 alkyl-O— having 1, 2, or 3 heteroatoms independently chosen from N, O, and S; (5- or 6-membered unsaturated or aromatic heterocycle)C 0 -C 4 alkyl-O— having 1, 2, or 3 heteroatoms independently chosen from N, O, and S; —O(CH 2 ) 2-4 O(CH 2 ) 8-18 , —OC(R 20a ) 2 OC(O)OR 20b , —OC(R 20a ) 2 OC(O)R 20b , —NR 9 R 10 , an N-linked amino acid or an N-linked amino acid ester and each R 20 can be optionally substituted;

R 20a is independently chosen at each occurrence from hydrogen, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, (aryl)C 0 -C 4 alkyl-, (aryl)C 2 -C 8 alkenyl- or (aryl)C 2 -C 8 alkynyl-; or

two R 20a groups can be taken together with the carbon that they are bonded to form a 3-6 membered heterocycloalkyl having 1, 2, or 3 heteroatoms independently chosen from N, O, and S, or a 3-6 membered carbocyclic ring;

R 20b is independently chosen at each occurrence from C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, (aryl)C 0 -C 4 alkyl, (aryl)C 2 -C 8 alkenyl or (aryl)C 2 -C 8 alkynyl;

R 11 and R 14 , are independently chosen at each occurrence from hydrogen, halogen, hydroxyl, nitro, cyano, —O(PO)(OR 9 ) 2 , —(PO)(OR 9 ) 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 2 -C 6 alkanoyl, C 1 -C 6 alkoxy, C 1 -C 6 thioalkyl, —C 0 -C 4 alkyl(mono- and di-C 1 -C 6 alkylamino), —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), —C 0 -C 4 alkoxy(C 3 -C 7 cycloalkyl), C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy;

R 21 and R 22 are independently chosen at each occurrence from hydrogen, hydroxyl, cyano, amino, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, (C 3 -C 7 cycloalkyl)C 0 -C 4 alkyl, (phenyl)C 0 -C 4 alkyl, —C 1 -C 4 alkylOC(O)OC 1 -C 6 alkyl, —C 1 -C 4 alkylOC(O)C 1 -C 6 alkyl, —C 1 -C 4 alkylC(O)OC 1 -C 6 alkyl, (4- to 7-membered heterocycloalkyl)C 0 -C 4 alkyl having 1, 2, or 3 heteroatoms independently chosen from N, O, and S, and (5- or 6-membered unsaturated or aromatic heterocycle)C 0 -C 4 alkyl having 1, 2, or 3 heteroatoms independently chosen from N, O, and S, and each R 21 and R 22 can be optionally substituted;

R 23 is independently chosen at each occurrence from C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, (aryl)C 0 -C 4 alkyl, (C 3 -C 7 cycloalkyl)C 0 -C 4 alkyl, (phenyl)C 0 -C 4 alkyl, (4- to 7-membered heterocycloalkyl)C 0 -C 4 alkyl having 1, 2, or 3 heteroatoms independently chosen from N, O, and S, and (5- or 6-membered unsaturated or aromatic heterocycle)C 0 -C 4 alkyl having 1, 2, or 3 heteroatoms independently chosen from N, O, and S, and each R 23 can be optionally substituted;

R 24 and R 25 are taken together with the nitrogen to which they are attached to form a 4- to 7-membered monocyclic heterocycloalkyl group, or a 6- to 10-membered bicyclic heterocyclic group having fused, spiro, or bridged rings, and each R 24 and R 25 can be optionally substituted;

L is a bond or is chosen from the formulas

where R 17 is hydrogen, C 1 -C 6 alkyl, or —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl) and R 18 and R 18′ are independently chosen from hydrogen, halogen, hydroxymethyl, and methyl; and m is 0, 1, 2, or 3;

—(C 0 -C 4 alkyl)(aryl); —(C 0 -C 4 alkyl)(heteroaryl); or —(C 0 -C 4 alkyl)(biphenyl) each of which B is unsubstituted or substituted with one or more substituents independently chosen from R 33 and R 34 , and 0 or 1 substituents chosen from R 35 and R 36 ;

or B is selected from the group consisting of

R 26 , R 27 , and R 28 are independently chosen from hydrogen, halogen, hydroxyl, nitro, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkanoyl, C 1 -C 6 alkoxy, C 1 -C 6 thioalkyl, (mono- and di-C 1 -C 6 alkylamino)C 0 -C 4 alkyl, (C 3 -C 7 cycloalkyl)C 0 -C 4 alkyl, (aryl)C 0 -C 4 alkyl-, (heteroaryl)C 0 -C 4 alkyl-, and —C 0 -C 4 alkoxy(C 3 -C 7 cycloalkyl); each of which R 26 , R 27 , and R 28 other than hydrogen, halogen, hydroxyl, nitro, cyano, is unsubstituted or substituted with one or more substituents independently chosen from halogen, hydroxyl, amino, C 1 -C 2 alkoxy, C 1 -C 2 haloalkyl, (C 3 -C 7 cycloalkyl)C 0 -C 4 alkyl-, and C 1 -C 2 haloalkoxy;

R 29 is hydrogen, C 1 -C 2 alkyl, C 1 C 2 haloalkyl or —Si(CH 3 ) 2 C(CH 3 ) 3 ;

R 33 is independently chosen from halogen, hydroxyl, —COOH, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkanoyl, C 1 -C 6 alkoxy, —C 0 -C 4 alkylNR 9 R 10 , —SO 2 R 9 , —C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy;

R 34 is independently chosen from nitro, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 thioalkyl, -JC 3 -C 7 cycloalkyl, —B(OH) 2 , -JC(O)NR 9 R 23 , -JOSO 2 OR 21 , —C(O)(CH 2 ) 1-4 S(O)R 21 , —O(CH 2 ) 1-4 S(O)NR 21 R 22 , -JOP(O)(OR 21 )(OR 22 ), -JP(O)(OR 21 )(OR 22 ), -JOP(O)(OR 21 )R 22 , -JP(O)(OR 21 )R 22 , -JOP(O)R 21 R 22 , -JP(O)R 21 R 22 , -JSP(O)(OR 21 )(OR 22 ), -JSP(O)(OR 21 )(R 22 ), -JSP(O)(R 21 )(R 22 ), -JNR 9 P(O)(NHR 21 )(NHR 22 ), -JNR 9 P(O)(OR 21 )(NHR 22 ), -JNR 9 P(O)(OR 21 )(OR 22 ), -JC(S)R 21 , -JNR 21 SO 2 R 22 , -JNR 9 S(O)NR 10 R 22 , -JNR 9 SO 2 NR 10 R 22 , -JSO 2 NR 9 COR 22 , -JSO 2 NR 9 CONR 21 R 22 , -JNR 21 SO 2 R 22 , -JC(O)NR 21 SO 2 R 22 , -JC(NH 2 )NR 22 , -JC(NH 2 )NR 9 S(O) 2 R 22 , -JOC(O)NR 21 R 22 , -JNR 21 C(O)OR 22 , -JNR 21 OC(O)R 22 , —(CH 2 ) 1-4 C(O)NR 21 R 22 , -JC(O)R 24 R 25 , -JNR 9 C(O)R 21 , -JC(O)R 21 , -JNR 9 C(O)NR 10 R 22 , —CCR 21 , —(CH 2 ) 1-4 OC(O)R 21 , and -JC(O)OR 23 ; each of which R 34 is unsubstituted or substituted with one or more substituents independently chosen from halogen, hydroxyl, nitro, cyano, amino, oxo, —B(OH) 2 , —Si(CH 3 ) 3 , —COOH, —CONH 2 , —P(O)(OH) 2 , C 1 -C 6 alkyl, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), C 1 -C 6 alkoxy, —C 0 -C 2 alkyl(mono- and di-C 1 -C 4 alkylamino), C 1 -C 6 alkylester, C 1 -C 4 alkylamino, C 1 -C 4 hydroxylalkyl, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy;

R 35 is independently chosen from naphthyl, naphthyloxy, indanyl, (4- to 7-membered heterocycloalkyl)C 0 -C 4 alkyl containing 1 or 2 heteroatoms chosen from N, O, and S, and bicyclic heterocycle containing 1, 2, or 3 heteroatoms independently chosen from N, O, and S, and containing 4- to 7-ring atoms in each ring; each of which R 35 is unsubstituted or substituted with one or more substituents independently chosen from halogen, hydroxyl, nitro, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkanoyl, C 1 -C 6 alkoxy, (mono- and di-C 1 -C 6 alkylamino)C 0 -C 4 alkyl, C 1 -C 6 alkylester, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), —SO 2 R 9 , C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy; and

R 36 is independently chosen from tetrazolyl, (phenyl)C 0 -C 2 alkyl, (phenyl)C 1 -C 2 alkoxy, phenoxy, and 5- or 6-membered heteroaryl containing 1, 2, or 3 heteroatoms independently chosen from N, O, B, and S, each of which R 36 is unsubstituted or substituted with one or more substituents independently chosen from halogen, hydroxyl, nitro, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkanoyl, C 1 -C 6 alkoxy, (mono- and di-C 1 -C 6 alkylamino)C 0 -C 4 alkyl, C 1 -C 6 alkylester, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), —SO 2 R 9 , —OSi(CH 3 ) 2 C(CH 3 ) 3 , —Si(CH 3 ) 2 C(CH 3 ) 3 , C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy; and

J is independently selected at each occurrence from a covalent bond, C 1 -C 4 alkylene, —OC 1 -C 4 alkylene, C 2 -C 4 alkenylene, and C 2 -C 4 alkynylene.

2. The compound of claim 1 , wherein the

ring is selected from:

3. The compound of claim 1 , wherein R 1 and R 2 are linked to form a 3- to 6-membered carbocyclic or aryl ring;

or R 2 and R 3 form a 3- to 6-membered carbocyclic ring;

or R 1 and R 1′ , or R 2 and R 2′ , or R 3 and R 3′ are linked to form a 3- to 6-membered carbocyclic spiro ring;

or R 2 and R 2′ , or R 3 and R 3′ are linked to form a 3- to 6-membered heterocyclic spiro ring;

each of which ring is unsubstituted or substituted with 1 or more substituents independently chosen from halogen, hydroxyl, cyano, —COOH, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, C 2 -C 4 alkanoyl, hydroxyC 1 -C 4 alkyl, (mono- and di-C 1 -C 4 alkylamino)C 0 -C 4 alkyl, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), —O—C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy.

4. The compound of claim 1 , wherein R 1 and R 1′ or R 2 and R 2′ are linked to form a carbonyl group.

5. The compound of claim 1 , wherein —L—B— is selected from:

wherein

R 18 and R 18′ are independently chosen from hydrogen, halogen, hydroxymethyl, and methyl;

m is 0 or 1; and

R 26 , R 27 , and R 28 are independently chosen from hydrogen, halogen, hydroxyl, nitro, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkanoyl, C 1 -C 6 alkoxy, C 1 -C 6 thioalkyl, (mono- and di-C 1 -C 6 alkylamino)C 0 -C 4 alkyl, (C 3 -C 7 cycloalkyl)C 0 -C 4 alkyl, (aryl)C 0 -C 4 alkyl-, (heteroaryl)C 0 -C 4 alkyl-, and —C 0 -C 4 alkoxy(C 3 -C 7 cycloalkyl); each of which R 26 , R 27 , and R 28 other than hydrogen, halogen, hydroxyl, nitro, cyano, is unsubstituted or substituted with one or more substituents independently chosen from halogen, hydroxyl, amino, C 1 -C 2 alkoxy, C 1 -C 2 haloalkyl, (C 3 -C 7 cycloalkyl)C 0 -C 4 alkyl-, and C 1 -C 2 haloalkoxy; and R 29 is hydrogen, C 1 -C 2 alkyl, C 1 C 2 haloalkyl or —Si(CH 3 ) 2 C(CH 3 ) 3 .

6. The compound of claim 1 , wherein B is selected from:

7. The compound of claim 1 , wherein R 32 is selected from:

8. The compound of claim 1 having the formula:

9. The compound of claim 8 , wherein:

B is 2-fluoro-3-chlorophenyl;

R 13 is R 32 ; and,

R 32 is —P(O)R 20 R 20 .

10. The compound of claim 9 , wherein at least one R 20 is hydroxyl.

11. The compound of claim 9 , wherein R 32 is selected from:

12. The compound of claim 9 , wherein the compound is:

13. The compound of claim 9 , wherein the compound is:

14. The compound of claim 9 , wherein the compound is:

15. The compound of claim 9 , wherein the compound is:

16. The compound of claim 9 , wherein the compound is:

17. The compound of claim 9 , wherein the compound is:

18. The compound of claim 9 , wherein the compound is:

19. The compound of claim 9 , wherein the compound is:

20. The compound of claim 9 , wherein the compound is:

21. The compound of claim 9 , wherein the compound is:

22. The compound of claim 9 , wherein the compound is:

23. The compound of claim 9 , wherein the compound is:

24. The compound of claim 9 , wherein the compound is:

25. The compound of claim 9 , wherein the compound is:

26. The compound of claim 9 , wherein the compound is:

27. The compound of claim 9 , wherein the compound is:

28. The compound of claim 9 , wherein the compound is:

29. The compound of claim 9 , wherein the compound is:

30. The compound of claim 9 , wherein the compound is:

31. The compound of claim 9 , wherein the compound is:

32. The compound of claim 9 , wherein the compound is:

33. The compound of claim 9 , wherein the compound is:

34. The compound of claim 1 , wherein the compound is:

35. The compound of claim 34 , wherein:

m is 0;

B is 2-fluoro-3-chlorophenyl;

R 12 is R 32 ; and,

R 32 is —P(O)R 20 R 20 .

36. The compound of claim 34 , wherein the compound is:

37. The compound of claim 34 , wherein the compound is:

38. The compound of claim 34 , wherein the compound is:

39. The compound of claim 1 , wherein the

ring is selected from:

40. The compound of claim 1 , wherein the

ring is selected from:

41. The compound of claim 1 , wherein B is selected from:

42. The compound of claim 1 , wherein B is selected from:

and

wherein

R 27 is hydrogen, methyl, or trifluoromethyl;

R 28 is hydrogen or halogen; and

R 29 is hydrogen, methyl, trifluoromethyl, or —Si(CH 3 ) 2 C(CH 3 ) 3 .

43. The compound of claim 1 , wherein B is selected from:

44. The compound of claim 1 , wherein B is selected from:

45. The compound of claim 1 , wherein R 32 is selected from:

46. The compound of claim 1 , wherein R 32 is selected from:

47. The compound of claim 1 , wherein R 32 is selected from:

48. The compound of claim 1 , wherein R 32 is selected from:

49. The compound of claim 1 , wherein R 32 is selected from:

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2016
From: WILES, JASON ALLAN; HASHIMOTO, AKIHIRO; GADHACHANDA, VENKAT RAO; PAIS, GODWIN; WANG, QIUPING; CHEN, DAWEI; WANG, XIANGZHU; AGARWAL, ATUL; DESHPANDE, MILIND; PHADKE, AVINASH S.
To: ACHILLION PHARMACEUTICALS, INC.
Reel/Frame 038593/0375 →
Continuity (4)
Provisional Application 61944189 · Feb 25, 2014
Provisional Application 62022916 · Jul 10, 2014
Provisional Application 62046783 · Sep 5, 2014
Related Publication 20150239921A1 · Aug 27, 2015